BeiGene (HKG:6160, SHA:688235) swung to a net loss of $121.4 million in the third quarter from a profit of $215.4 million in the year-ago period.
The drugmaker incurred a loss per share of $0.09, reversing earnings per share of $0.15 in the previous year, according to a Wednesday filing with the Hong Kong Exchange.
Total revenue jumped to $1 billion from $781.3 million a year earlier, driven by growth in BRUKINSA product sales in the US and Europe.
Shares slid 3% in Hong Kong during Wednesday's morning trading.
Price (HKD): $116.90, Change: $-4.9, Percent Change: -4.02%